首页> 外文期刊>European urology >Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
【24h】

Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.

机译:与普通人群的肾癌相比,患有终末期肾病的患者的肾细胞癌(RCC)具有许多有利的临床,病理和预后特征。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Patients with end-stage renal disease (ESRD) are at risk of developing renal tumours. OBJECTIVE: Compare clinical, pathologic, and outcome features of renal cell carcinomas (RCCs) in ESRD patients and in patients from the general population. DESIGN, SETTING, AND PARTICIPANTS: Twenty-four French university departments of urology participated in this retrospective study. INTERVENTION: All patients were treated according to current European Association of Urology guidelines. MEASUREMENTS: Age, sex, symptoms, tumour staging and grading, histologic subtype, and outcome were recorded in a unique database. Categoric and continuous variables were compared by using chi-square and student statistical analyses. Cancer-specific survival (CSS) was assessed by Kaplan-Meier and Cox methods. RESULTS AND LIMITATIONS: The study included 1250 RCC patients: 303 with ESRD and 947 from the general population. In the ESRD patients, age at diagnosis was younger (55 +/- 12 yr vs 62 +/- 12 yr); mean tumour size was smaller (3.7 +/- 2.6 cm vs 7.3 +/- 3.8 cm); asymptomatic (87% vs 44%), low-grade (68% vs 42%), and papillary tumours were more frequent (37% vs 7%); and poor performance status (PS; 24% vs 37%) and advanced T categories (>/= 3) were more rare (10% vs 42%). Consistently, nodal invasion (3% vs 12%) and distant metastases (2% vs 15%) occurred less frequently in ESRD patients. After a median follow-up of 33 mo (range: 1-299 mo), 13 ESRD patients (4.3%), and 261 general population patients (27.6%) had died from cancer. In univariate analysis, histologic subtype, symptoms at diagnosis, poor PS, advanced TNM stage, high Fuhrman grade, large tumour size, and non-ESRD diagnosis context were adverse predictors for survival. However, only PS, TNM stage, and Fuhrman grade remained independent CSS predictors in multivariate analysis. The limitation of this study is related to the retrospective design. CONCLUSIONS: RCC arising in native kidneys of ESRD patients seems to exhibit many favourable clinical, pathologic, and outcome features compared with those diagnosed in patients from the general population.
机译:背景:患有终末期肾病(ESRD)的患者有发展为肾脏肿瘤的风险。目的:比较ESRD患者和普通人群中肾细胞癌(RCC)的临床,病理和预后特征。设计,地点和参与者:24个法国大学泌尿外科系参加了这项回顾性研究。干预:所有患者均根据欧洲泌尿外科协会现行指南进行治疗。测量:年龄,性别,症状,肿瘤分期和分级,组织学亚型和结果记录在一个独特的数据库中。使用卡方和学生统计分析比较分类变量和连续变量。通过Kaplan-Meier和Cox方法评估癌症特异性生存率(CSS)。结果与局限性:该研究纳入了1250例RCC患者:303例ESRD患者和947例普通人群。在ESRD患者中,诊断时年龄更小(55 +/- 12岁对62 +/- 12岁)。平均肿瘤尺寸更小(3.7 +/- 2.6 cm与7.3 +/- 3.8 cm);无症状(87%vs 44%),低度(68%vs 42%)和乳头状肿瘤更常见(37%vs 7%);较差的表现状态(PS; 24%比37%)和高级T类(> / = 3)更罕见(10%比42%)。一致地,ESRD患者的淋巴结转移(3%vs 12%)和远处转移(2%vs 15%)的发生率较低。在中位随访33个月(范围:1-299个月)后,有13例ESRD患者(4.3%)和261例一般人群患者(27.6%)死于癌症。在单因素分析中,组织学亚型,诊断时的症状,PS差,TNM分期晚期,Fuhrman分级高,肿瘤大和非ESRD诊断是生存的不良预测因素。但是,在多变量分析中,只有PS,TNM分期和Fuhrman评分仍然是独立的CSS预测指标。这项研究的局限性与回顾性设计有关。结论:与普通人群患者相比,ESRD患者天然肾脏中产生的RCC似乎具有许多有利的临床,病理和预后特征。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号